Top Markets
#1 Siren Siren +35.01%
#2 Wiki Cat Wiki Cat +25.21%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.95%
#4 Ribbita by Virtuals Ribbita by Virtuals +19.07%
#5 PulseChain PulseChain +17.42%
#6 KUB Coin KUB Coin +16.79%
#7 Cysic Cysic +16.04%
#8 Velvet Velvet +15.70%
#9 TROLL TROLL +15.34%
#10 The Grays Currency The Grays Currency +15.09%
Coin of the day
Siren Siren
Settings
Language
ENGLISH
Currency
USD
Theme
NeuroSense Therapeutics Ltd. NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NRSN
Rank in Stocks #31074
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical... NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Share Price
$0.404
Market Cap
$14.28M
Change (1 day)
-10.42%
Change (1 year)
-67.68%
Country
IL
Trade NeuroSense Therapeutics Ltd. (NRSN)

Category

Healthcare
Revenue for NeuroSense Therapeutics Ltd. (NRSN)
Revenue in Aug 2026 TTM: 0
According to NeuroSense Therapeutics Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for NeuroSense Therapeutics Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE